ストックスクリーナーアプリを入手
336.33
0.12%
-0.3418
前日終値:
$336.67
開ける：
$339.48
24時間の取引高:
46,242
Relative Volume:
0.12
時価総額：
$9.95B
収益：
$417.30M
当期純損益:
$225.03M
株価収益率:
44.95
EPS:
7.4815
ネットキャッシュフロー:
$237.38M
1週間 パフォーマンス:
-1.11%
1か月 パフォーマンス:
-2.98%
6か月 パフォーマンス:
+33.61%
1年 パフォーマンス:
+105.58%
1日の値動き範囲:
$334.54
$341.15
1週間の範囲:
$331.79
$346.20
52週間の値動き範囲:
$158.08
$382.54
Krystal Biotech Inc Stock (KRYS) Company Profile
名前
Krystal Biotech Inc
セクター
電話
(412) 586-5830
住所
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
336.18 | 10.27B | 417.30M | 225.03M | 237.38M | 7.4815 |
VRTX
Vertex Pharmaceuticals Inc
|
510.31 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.00 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
168.31 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
997.54 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
193.26 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-27 | 開始されました | Wolfe Research | Peer Perform |
| 2026-01-06 | アップグレード | Citigroup | Neutral → Buy |
| 2025-03-05 | 開始されました | Jefferies | Buy |
| 2024-08-06 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-11-20 | 開始されました | Goldman | Buy |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-12 | 開始されました | Citigroup | Buy |
| 2023-09-07 | 開始されました | Berenberg | Buy |
| 2023-04-18 | 開始されました | Stifel | Buy |
| 2023-02-28 | アップグレード | Goldman | Neutral → Buy |
| 2022-08-25 | ダウングレード | Goldman | Buy → Neutral |
| 2022-01-18 | 開始されました | BofA Securities | Buy |
| 2021-07-20 | アップグレード | Goldman | Neutral → Buy |
| 2020-09-18 | 開始されました | B. Riley FBR | Buy |
| 2020-06-04 | 開始されました | Evercore ISI | Outperform |
| 2019-09-24 | 開始されました | Goldman | Neutral |
| 2019-08-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-06-24 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-06-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-05-30 | 開始されました | Guggenheim | Buy |
| 2018-09-11 | 開始されました | Cantor Fitzgerald | Overweight |
すべてを表示
Krystal Biotech Inc (KRYS) 最新ニュース
(KRYS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
What Put Krystal Biotech (KRYS) in Focus? - Kalkine Media
Krystal Biotech at Cantor healthcare conference: pipeline gains pace By Investing.com - Investing.com Canada
KRYS: International expansion and pipeline progress set the stage for multi-product growth - TradingView
Krystal Biotech at Cantor healthcare conference: pipeline gains pace - Investing.com
Here’s How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years - Benzinga
Krystal Biotech CEO Krishnan Krish S Sells 25,000 Shares at Prices Up to $366.56 on September 4, 2026 - Kalkine Media
Krystal Biotech President Krishnan Suma Disposes of 25,000 Shares at $354.54-$366.56 (NASDAQ: KRYS) - Kalkine Media
Krystal Biotech Insider Sold Shares Worth $8,983,084, According to a Recent SEC Filing - marketscreener.com
Krystal Biotech Insider Sold Shares Worth $8,982,986, According to a Recent SEC Filing - marketscreener.com
Krystal Biotech, Inc. (KRYS) Stock Analysis: Unveiling a 7.47% Potential Upside with Promising Genetic Medicine Innovations - DirectorsTalk Interviews
Krystal Biotech president, R&D Suma Krishnan sells $8.98m in stock By Investing.com - Investing.com South Africa
Krystal Biotech CEO Krish S. Krishnan sells $8.98m in company stock By Investing.com - Investing.com Australia
Krystal Biotech CEO Krish S. Krishnan sells $8.98m in company stock - Investing.com Nigeria
Krystal Biotech president, R&D Suma Krishnan sells $8.98m in stock - Investing.com Nigeria
Krystal Biotech(KRYS.US) 10% Shareholder Sells US$8.98 Million in Common Stock - Moomoo
Krystal Biotech (KRYS) R&D head sells 25,000 shares under trading plan - Stock Titan
Krystal Biotech (NASDAQ: KRYS) CEO sells 25,000 shares under trading plan - Stock Titan
Krystal Biotech (NASDAQ: KRYS) holder to sell 25,000 founders shares - Stock Titan
Krystal Biotech (KRYS) insider moves to sell 2017 shares in a multimillion-dollar deal - Stock Titan
Krystal Biotech stock steadies as regulatory debate over Vyjuvek intensifies - ad-hoc-news.de
Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally? - TradingView
Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference - The Manila Times
Krystal Biotech to Participate in 2026 Cantor Global Healthcare Conference - Quiver Quantitative
A healthcare conference webcast is set for Sept. 10 in New York - Stock Titan
Krystal Biotech stock gains on solid Q2 2026 Vyjuvek growth - ad-hoc-news.de
Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Krystal Biotech, Inc. (KRYS) Stock Analysis: Strong Buy Ratings And 9.54% Potential Upside - DirectorsTalk Interviews
Krystal Biotech, Inc. (KRYS) Stock Analysis: Discovering a 11% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Krystal Biotech Stock Soars 16% in Three Months: Here's Why - Eastern Progress
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Krystal Biotech Set to Join S&P MidCap 400; Tutor Perini and V2X to Join S&P SmallCap 600 - Eastern Progress
KRYS Stock Rallies On Upbeat Earnings: Jefferies Ups Price Target On Sustained Vyjuvek Optimism - Stocktwits
Krystal Biotech Inc (MIL:1KRYS) Stock Price, Trades & News - GuruFocus
Krystal Biotech, Inc. (KRYS) Stock Analysis: Exploring The 15.87% Upside Potential - DirectorsTalk Interviews
Krystal Biotech Insider Sold Shares Worth $8,227,953, According to a Recent SEC Filing - marketscreener.com
State of Wyoming Buys New Stake in Krystal Biotech, Inc. $KRYS - MarketBeat
Should Surging Vyjuvek-Driven Earnings Reshape How Krystal Biotech (KRYS) Investors View Its Risk Profile? - simplywall.st
Krystal Biotech (KRYS) Has a New Rating from RBC Capital - The Globe and Mail
Krystal Biotech (NASDAQ:KRYS) Upgraded to "Moderate Buy" at Royal Bank Of Canada - MarketBeat
Krystal Biotech (KRYS) Director Dino Rossi Sells 25,000 Shares - GuruFocus
Krystal Biotech(KRYS.US) Director Sells US$8.23 Million in Common Stock - Moomoo
Krystal Biotech (KRYS) Advances 1.2% to $332.27, Holding Ground Above Key SupportAggressive Growth Picks - vinanet.vn
Krystal Biotech (NASDAQ:KRYS) director Dino Rossi sells $8.2m shares - Investing.com Australia
Dino Rossi Sells 25,000 Shares of Krystal Biotech (NASDAQ:KRYS) Stock - MarketBeat
Krystal Biotech, Inc. SEC Filing (Aug 14, 2026) - Stock Titan
Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More - The Globe and Mail
RBC Capital Initiates Krystal Biotech(KRYS.US) With Buy Rating, Announces Target Price $400 - moomoo.com
KRYS Looks 0.5% Undervalued on GF Value™ - GuruFocus
Krystal Biotech Seen Positioned for Further Gains on Vyjuvek, Pipeline Readouts, RBC Says - marketscreener.com
KRYS Initiates Coverage by RBC Capital -- Rating Set to Outperfo - GuruFocus
Krystal Biotech Inc (KRYS) 財務データ
収益
当期純利益
現金流量
EPS
Krystal Biotech Inc (KRYS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Krishnan Krish S | President and CEO |
Sep 04 '26 |
Sale |
359.32 |
25,000 |
8,983,084 |
1,347,543 |
0.48%
1.69%
大文字化:
|
ボリューム (24 時間):